1-2 of 2
Lin Ping
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)

Matthew C. Riddle, MD, Ronnie Aronson, MD, FRCPC, FACE, Philip Home, DPHIL, DM, FRCP, Michel Marre, MD, PHD, Elisabeth Niemoeller, MD, Patrick Miossec, MD, Lin Ping, MD, Jenny Ye, Julio Rosenstock, MD
Journal: Diabetes Care
Diabetes Care 2013;36(9):2489–2496
https://doi.org/10.2337/dc12-2454
Published: 13 August 2013
View article titled, Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: <subtitle>A 24-week, randomized, placebo-controlled comparison (GetGoal-L)</subtitle>
Open the PDF for Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: <subtitle>A 24-week, randomized, placebo-controlled comparison (GetGoal-L)</subtitle> in another window
Includes: Supplementary data
Journal Articles

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)

Matthew C. Riddle, MD, Thomas Forst, MD, Ronnie Aronson, MD, Leobardo Sauque-Reyna, MD, Elisabeth Souhami, MD, Louise Silvestre, MD, Lin Ping, MD, Julio Rosenstock, MD
Journal: Diabetes Care
Diabetes Care 2013;36(9):2497–2503
https://doi.org/10.2337/dc12-2462
Published: 13 August 2013
View article titled, Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: <subtitle>A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)</subtitle>
Open the PDF for Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: <subtitle>A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)</subtitle> in another window
Includes: Supplementary data